Icelandic researchers uncover genetic variations linked to cancer risk in groundbreaking study

Recent advancements in genetic research conducted by Icelandic scientists are expected to enhance cancer screening and treatment methods. Researchers at deCODE Genetics have identified genetic variations in six genes that increase the likelihood of cancer diagnoses. This discovery is anticipated to lead to earlier detection of cancerous conditions and the development of targeted therapies for patients carrying these mutations.

Among the identified genes, BRCA1 and BRCA2 mutations are known to elevate the risk of breast and ovarian cancers, along with several other cancer types. Such mutations are relatively rare in Iceland. The research utilized sequencing data from Iceland, Norway, and the United Kingdom to uncover four genes associated with an increased risk of developing various cancers, including prostate, colorectal, thyroid, lung, and melanoma.

The team compared genomic data from 130,991 cancer patients with information from 733,486 individuals without cancer. They examined gene variants that either disable or diminish the activity of certain genes and explored their correlation with 22 different cancer forms.

Additionally, researchers identified genes where loss-of-function mutations have a protective effect against cancer. Specifically, reduced activity of the AURKB gene appears to provide protection against cancer, regardless of its location in the body. Individuals with a loss-of-function mutation in the PPP1R15A gene are 53% less likely to be diagnosed with breast cancer, suggesting potential therapeutic avenues targeting this gene or its protein products.

This research, published in Nature Genetics, is expected to pave the way for improved cancer screening methods and the development of more effective cancer treatments in the future.